CO6501184A2 - Kit de formulaciones farmaceuticas caracterizado por la presencia de oxigeno molecular - Google Patents

Kit de formulaciones farmaceuticas caracterizado por la presencia de oxigeno molecular

Info

Publication number
CO6501184A2
CO6501184A2 CO11058004A CO11058004A CO6501184A2 CO 6501184 A2 CO6501184 A2 CO 6501184A2 CO 11058004 A CO11058004 A CO 11058004A CO 11058004 A CO11058004 A CO 11058004A CO 6501184 A2 CO6501184 A2 CO 6501184A2
Authority
CO
Colombia
Prior art keywords
increase
decrease
patient
pharmaceutical formulations
molecular oxygen
Prior art date
Application number
CO11058004A
Other languages
English (en)
Inventor
Alcalde David Izquierdo
Original Assignee
Comercializadora S Car Borr S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42170563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6501184(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Comercializadora S Car Borr S A De C V filed Critical Comercializadora S Car Borr S A De C V
Publication of CO6501184A2 publication Critical patent/CO6501184A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/064—Saccharomycetales, e.g. baker's yeast
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

Kit de formulaciones farmacéuticas caracterizado por la presencia de oxígeno molecular, integrado por cuatro elementos, que al unirse dan beneficios a la salud de pacientes con VIH SIDA.i. Aumento en el peso del paciente.ii. Aumento del Apetito.iii. Disminución de diarreas.iv. Disminución de Síndrome de Desgaste.v. Aumento en la estabilidad del talante.vi. Incremento en la masa muscular.vii. Disminución de las enfermedades oportunistas, en especial infecciones provocadas por cándida, herpes virus, citomegalovirus, sarkoma de kaposi.viii. Prolonga el tiempo en que el paciente no necesita tomar antiretrovirales.ix. Aumento en el apego de tratamiento farmacológico.x. Disminución en gastritis, náuseas o vómitos, cefaléa.xi. Disminución en casos con anemia o plaquetopenia.Un cambio en el estadio de la enfermedad en el paciente.
CO11058004A 2008-11-13 2011-05-11 Kit de formulaciones farmaceuticas caracterizado por la presencia de oxigeno molecular CO6501184A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2008014493A MX351356B (es) 2008-11-13 2008-11-13 Kit de formulaciones farmaceuticas caracterizado por la presencia de oxigeno molecular.
PCT/MX2009/000122 WO2010056100A2 (es) 2008-11-13 2009-11-13 Kit de formulaciones farmacéuticas caracterizado por la presencia de oxígeno molecular

Publications (1)

Publication Number Publication Date
CO6501184A2 true CO6501184A2 (es) 2012-08-15

Family

ID=42170563

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11058004A CO6501184A2 (es) 2008-11-13 2011-05-11 Kit de formulaciones farmaceuticas caracterizado por la presencia de oxigeno molecular

Country Status (8)

Country Link
US (1) US8778405B2 (es)
EP (1) EP2347662A4 (es)
BR (1) BRPI0921091A2 (es)
CA (1) CA2743495A1 (es)
CL (1) CL2011001079A1 (es)
CO (1) CO6501184A2 (es)
MX (1) MX351356B (es)
WO (1) WO2010056100A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325400A1 (en) * 2015-07-17 2018-05-30 ABL IP Holding LLC Software configurable lighting device
IT201800005508A1 (it) * 2018-05-18 2019-11-18 Kit per uso come integratore alimentare nel trattamento delle carenze di vitamine e/o minerali in ambito pediatrico.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU587863B2 (en) * 1985-10-07 1989-08-31 Basf Aktiengesellschaft Vitamin-containing granules and production thereof
EP0295961A3 (en) 1987-06-18 1989-07-12 Kureha Kagaku Kogyo Kabushiki Kaisha Polysaccharides and antiviral drug containing polysaccharides as active ingredient
JP2522946B2 (ja) * 1987-06-18 1996-08-07 呉羽化学工業株式会社 抗レトロウイルス剤
NL1010770C2 (nl) * 1998-12-09 2000-06-13 Nutricia Nv Preparaat dat oligosacchariden en probiotica bevat.
US6383534B1 (en) * 2000-01-18 2002-05-07 Lorin Dyrr Mineral water composition
DK1155620T3 (da) * 2000-05-18 2005-12-05 Mega Healthcare As Q Kosttilskudsmiddel med vitaminer, mineraler og flerumættede fedtsyrer
US20030232114A1 (en) * 2002-06-13 2003-12-18 Nikola Dekleva Method for liquid enrichment with oxygen and applications of enriched liquids
AU2002321678A1 (en) * 2002-09-09 2004-03-29 Boros Béla Oxygen-enriched water, treated within a magnetic field and heavy water
ATE471665T1 (de) * 2005-04-21 2010-07-15 Nutricia Nv Nahrungsergänzungsmittel für hiv-patienten
FR2901138A1 (fr) * 2006-05-19 2007-11-23 Lesaffre & Cie Compositions de micro-organismes probiotiques, granules les contenant, leur procede de preparation et leurs utilisations
US8491937B2 (en) * 2007-02-15 2013-07-23 Wyeth Llc Stability in vitamin and mineral supplements

Also Published As

Publication number Publication date
CA2743495A1 (en) 2010-05-20
US20120009273A1 (en) 2012-01-12
WO2010056100A3 (es) 2010-07-15
CL2011001079A1 (es) 2012-01-06
WO2010056100A2 (es) 2010-05-20
US8778405B2 (en) 2014-07-15
BRPI0921091A2 (pt) 2015-08-18
MX2008014493A (es) 2010-05-13
EP2347662A2 (en) 2011-07-27
EP2347662A4 (en) 2012-11-28
MX351356B (es) 2017-10-04

Similar Documents

Publication Publication Date Title
CY1122291T1 (el) Αναστολeις ιικου αναδιπλασιασμου
CU20110208A7 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
CY1110665T1 (el) Αναστολεις hiv ιντεγκρασης
BRPI0921482A8 (pt) Uso de uma construção de anticorpo de cadeia simples biespecífica cd19xcd3 no tratamento de leucemia linfoblástica aguda
DOP2006000096A (es) Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion
BRPI0518093A (pt) dose de nanopartìculas a um paciente, método de intensificação do transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro e dose oral de nanopartìculas que intensifica o transporte paracelular intestinal ou o transporte paracelular de sangue do cérebro
MY153900A (en) Antiviral composition comprising a sulfated polysaccharide
EA200970224A1 (ru) Лечение заболеваний хряща
CR20120289A (es) Derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol
AR069674A1 (es) Nanoparticulas que contienen farmaco
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
UY29189A1 (es) Nonadepsipeptidos acilados ii
CO6501184A2 (es) Kit de formulaciones farmaceuticas caracterizado por la presencia de oxigeno molecular
CY1115955T1 (el) Ενα στερεο φαρμακευτικο σκευασμα
ATE410443T1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE455789T1 (de) Substituierte nonadepsipeptide
CO6630124A2 (es) Terapia de combinación que comprende un antagonista de ccr5, un inhibidor de proteasa de vih-1, y un potenciador farmacocinético
WO2008076824A3 (en) Therapeutic and diagnostic peptides
CO5750041A1 (es) Metodo para la fabricacion de un medicamento a base de una mezcla de acidos grasos poliinsaturados para la prevencion de infecciones respiratorias en infantes
BR112022001564A2 (pt) Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv
Bombarda et al. Anti-adhesive and anti-biofilm activity of NC-E08. In vitro and in vivo study using Galleria mellonella infection model
MX2021010425A (es) Cadinanos de heterotheca inuloides (asteraceae) como sensibilizadores de cepas bacterianas resistentes.
CL2009000965A1 (es) Tableta oral compuesta por un compuesto i que comprende un 10 a 20% en peso de la tableta o su sal farmaceuticamente aceptable, que comprende ademas de un agente aglutinante, un desintegrante, un diluyente; proceso de preparacion de la tableta; y su uso en el tratamiento de vih y enfermedades inflamatorias.
CY1112771T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει αρτεσουνατη, σουλφαμεθοξυπυραζινη και πυριμεθαμινη για χρηση στην αντιμετωπιση ελονοσιας εντος μιας ημερας
Sicard Various toxicities: 6 case reports

Legal Events

Date Code Title Description
FC Application refused